Molecule Heart reports MMDesign antibody design results across 18 targets
Overview
Molecule Heart (分子之心) says its MMDesign AI protein design platform produced experimentally confirmed binders in 18 of 19 de novo design projects, a 94.7% project success rate.
The projects cover 18 targets and two molecule types, VHH nanobodies and macrocyclic peptides, with 9 to 50 candidates tested per project.
Across the projects, 139 of 453 tested candidates bound, a 30.7% candidate hit rate, according to the company's technical report as reported by QbitAI (量子位). All six GPCR targets tested produced successful binders, with best affinities in the nanomolar range.
Written by AI from the articles below · updated Oct 28, 1:05 PM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- QbitAINewsMolecular Mind's MMDesign hits 18 of 19 antibody design projects in lab tests
AIMolecular Mind says its MMDesign platform produced experimentally confirmed binders in 18 of 19 de novo design projects, a 94.7% project success rate. The company reports 139 of 453 tested candidates bound, a 30.7% candidate hit rate, including all six GPCR targets tested, with best affinities in the nanomolar range.
Heat Trend
Not enough continuous observations to show a trend yet.